Orchard Therapeutics plc
ORTX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $6,302 | $7,314 | $1,237 | $6,986 |
| % Growth | -13.8% | 491.3% | -82.3% | – |
| Cost of Goods Sold | $1,745 | $2,189 | $367 | -$1,905 |
| Gross Profit | $4,557 | $5,125 | $870 | $8,891 |
| % Margin | 72.3% | 70.1% | 70.3% | 127.3% |
| R&D Expenses | $14,553 | $16,695 | $15,993 | -$42,757 |
| G&A Expenses | $10,834 | $10,059 | $10,297 | $9,705 |
| SG&A Expenses | $11,609 | $10,992 | $11,135 | -$27,592 |
| Sales & Mktg Exp. | $775 | $933 | $838 | $895 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26,162 | $27,687 | $27,128 | -$70,349 |
| Operating Income | -$21,605 | -$22,562 | -$26,258 | $133,076 |
| % Margin | -342.8% | -308.5% | -2,122.7% | 1,904.9% |
| Other Income/Exp. Net | -$12,738 | $10,280 | $8,834 | $22,577 |
| Pre-Tax Income | -$34,343 | -$12,282 | -$17,424 | $135,010 |
| Tax Expense | $976 | $25 | -$12 | $116 |
| Net Income | -$35,319 | -$12,307 | -$17,412 | $134,894 |
| % Margin | -560.4% | -168.3% | -1,407.6% | 1,930.9% |
| EPS | -1.55 | -0.65 | -1.23 | 10.52 |
| % Growth | -138.5% | 47.2% | -111.7% | – |
| EPS Diluted | -1.55 | -0.65 | -1.23 | 10.52 |
| Weighted Avg Shares Out | 22,839 | 18,929 | 14,181 | 12,821 |
| Weighted Avg Shares Out Dil | 22,839 | 18,929 | 14,181 | 12,821 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,505 | $1,391 | $1,029 | $857 |
| Interest Expense | $932 | $975 | $957 | $933 |
| Depreciation & Amortization | $652 | $3,049 | $6,582 | $721 |
| EBITDA | -$34,623 | -$19,513 | -$19,676 | $133,797 |
| % Margin | -549.4% | -266.8% | -1,590.6% | 1,915.2% |